Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Sarepta Therapeutics, Inc. incurred convertible notes of approximately $291.4 million with certain holders (including Michael A. Chambers Living Trust) at 4.875% maturing due 2030.
- Instrument
- convertible notes
- Principal
- approximately $291.4 million
- Counterparty
- certain holders (including Michael A. Chambers Living Trust)
- Rate
- 4.875%
- Maturity
- due 2030
- Event
- incurrence
Exact text from the filing
the holders party thereto agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”) and (ii) an aggregate of approximately $31.6 million in cash.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Sarepta Therapeutics, Inc. entered into First Supplemental Indenture with U.S. Bank Trust Company, National Association (effective 2025-12-18).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Effective
- 2025-12-18
Exact text from the filing
the First Supplemental Indenture (the “First Supplemental Indenture”), dated as of December 18, 2025, each between the Company and U.S. Bank Trust Company, National Association, as trustee
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Sarepta Therapeutics, Inc. entered into Exchange Agreements with certain holders of its 1.25% Convertible Senior Notes due 2027 valued at approximately $291.4 million in aggregate principal amount of Existing Convertible Notes (effective 2025-12-10).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- certain holders of its 1.25% Convertible Senior Notes due 2027
- Value
- approximately $291.4 million in aggregate principal amount of Existing Convertible Notes
- Effective
- 2025-12-10
Exact text from the filing
on December 10, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”)
View on SEC.gov